Brief: Essex Bio-Technology Received Positive Outcome Of U.S. FDA - Second Phase 3 Clinical Trial In Dry Eye Disease
Feb 24 (Reuters) - Essex Bio-Technology Ltd 1061.HK :
* POSITIVE OUTCOME OF U.S. FDA- SECOND PHASE 3 CLINICAL
TRIAL- IN
DRY EYE DISEASE
Source text for Eikon: ID:nHKS2pwfD9
Further company coverage: 1061.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Essex Bio-Technology
See all newsHong Kong's Essex Bio-Technology H1 revenue falls
Brief: Essex Bio-Technology Posts HY Profit Of HK$110.7 MLN
Brief: Essex Bio-Technology Expects 10% Revenue And 30% Profit Decrease For HY
Brief: Shanghai Henlius Biotech Says Phase 3 Study Of HLX04-O For WAMD Meets Primary Endpoint
Brief: Essex Bio-Technology Posts Final Dividend Of HK$0.07 Per Share